Is SS-31 Safe? Safety Profile 2026 — PeptidePrices

Q: Is SS-31 safe?

SS-31 has a safety rating of 8/10 in our methodology — good. FDA-approved Sept 2025; 600+ patients in trials; injection site reactions main AE; well-tolerated

Q: Is SS-31 FDA approved?

FDA status: FDA-approved (Barth Syndrome). PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified SS-31?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest SS-31 listings for prices ranked by COA tier and $/mg.

Safety Profile

SS-31

Updated today

Mitochondrial Peptide

8/10Good

How we score compound safety →

Primary use: Mitochondrial research

Regulatory Status

FDA-approved (Barth Syndrome)

Safety Summary

FDA-approved Sept 2025
600+ patients in trials
injection site reactions main AE
well-tolerated

SS-31 sits in our well-studied tier (8/10). The safety dataset is robust, mechanisms are characterized, and side-effect patterns are predictable. Researchers working with this compound should still verify vendor COA quality — a clean safety profile means nothing if the vial contains the wrong compound or is under-dosed. Researchers often consider MOTS-c and Humanin as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeMitochondria-targeting tetrapeptide

Molecular Weight639.79 g/mol

Amino Acids4

CAS Number736992-21-5

SequenceD-Arg-Dmt-Lys-Phe-NH₂

Storage

Lyophilized−20°C, long-term stable

Reconstituted2–8°C, within 30 days

Protect from light
Avoid repeated freeze-thaw

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with SS-31

Full SS-31 profile Cheapest SS-31 deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.